Tg Therapeutics Inc. | Mid-cap | Healthcare
$36.29
2.51%
| Tg Therapeutics Stock Comparison:
Tg Therapeutics vs VertexTg Therapeutics vs RegeneronTg Therapeutics vs Blueprint MedicinesTg Therapeutics vs Roivant SciencesTg Therapeutics vs Bio-TechneTg Therapeutics vs S&P 500 | Market
Overview Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

Financial Overview

Latest Annual: 2024

Income Metrics

Revenue 329.0M
Gross Profit 290.5M 88.30%
Operating Income 41.9M 12.74%
Net Income 23.4M 7.11%
EPS (Diluted) $0.15

Balance Sheet Metrics

Total Assets 577.7M
Total Liabilities 355.3M
Shareholders Equity 222.4M
Debt to Equity 1.60

Cash Flow Metrics

Operating Cash Flow -61.7M
Free Cash Flow -40.6M

Revenue & Profitability Trend

Tg Therapeutics Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue 329.0M 233.7M 2.8M 6.7M 152.0K
Cost of Goods Sold 38.5M 14.1M 265.0K 790.0K 0
Gross Profit 290.5M 219.5M 2.5M 5.9M 152.0K
Operating Expenses 248.6M 198.9M 195.4M 350.7M 273.7M
Operating Income 41.9M 20.6M -192.8M -344.8M -273.6M
Pre-tax Income 25.6M 13.1M -198.3M -348.1M -279.4M
Income Tax 2.2M 390.0K 0 0 -
Net Income 23.4M 12.7M -198.3M -348.1M -279.4M
EPS (Diluted) $0.15 $0.09 -$1.46 -$2.63 -$2.42

Income Statement Trend

Tg Therapeutics Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets 566.4M 317.9M 168.3M 331.0M 611.7M
Non-Current Assets 11.3M 11.6M 25.3M 48.7M 13.9M
Total Assets 577.7M 329.6M 193.6M 379.6M 625.6M
Liabilities
Current Liabilities 90.7M 53.7M 53.2M 65.4M 87.6M
Non-Current Liabilities 264.6M 115.4M 81.8M 77.1M 18.7M
Total Liabilities 355.3M 169.1M 135.0M 142.5M 106.3M
Equity
Total Shareholders Equity 222.4M 160.5M 58.6M 237.2M 519.4M

Balance Sheet Composition

Tg Therapeutics Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income 23.4M 12.7M -198.3M -348.1M -279.4M
Operating Cash Flow -61.7M -29.4M -164.8M -312.1M -214.5M
Investing Activities
Capital Expenditures -45.0K 0 -14.0K -401.0K -357.0K
Investing Cash Flow -1.0M -50.7M -20.0M -332.0K -24.5M
Financing Activities
Dividends Paid - - - 0 0
Financing Cash Flow 127.6M 71.2M -975.0K 41.2M 679.7M
Free Cash Flow -40.6M -31.4M -176.2M -296.0M -214.9M

Cash Flow Trend

Tg Therapeutics Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 148.68
Forward P/E 38.32
Price to Book 22.75
Price to Sales 15.27
PEG Ratio 38.32

Profitability Ratios

Profit Margin 10.13%
Operating Margin 7.13%
Return on Equity 19.70%
Return on Assets 7.26%

Financial Health

Current Ratio 4.02
Debt to Equity 107.29
Beta 1.94

Per Share Data

EPS (TTM) $0.25
Book Value per Share $1.63
Revenue per Share $2.66

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
tgtx 5.9B 148.68 22.75 19.70% 10.13% 107.29
Vertex 114.1B 32.82 6.92 -5.64% -8.91% 10.00
Regeneron 55.3B 13.02 1.84 15.96% 31.94% 9.20
Blueprint Medicines 8.3B -120.00 24.19 -47.71% -27.70% 208.50
Roivant Sciences 7.8B 1.95 1.71 -12.54% 96.86% 1.93
Bio-Techne 7.9B 60.87 3.92 6.53% 10.89% 20.99

Financial data is updated regularly. All figures are in the company's reporting currency.